DIACEUTICS PLC

Report Publication Announcement • Mar 20, 2023

National Storage Mechanism | Additional information

RNS Number : 4159T

Diaceutics PLC

20 March 2023

20 March 2023

Diaceutics PLC

("Diaceutics" or "the Company")

Notice of Results and Presentations

Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, confirms that it expects to announce its audited Final Year results for the year end 31 December 2022 on 17 April 2023.

Analyst Presentation

A webinar presentation for analysts will be held at 9am on Monday, 17 April 2023. Analysts wishing to attend should register their interest in advance with diaceutics@almapr.co.uk.

Investor Presentation

Peter Keeling, CEO and Nick Roberts, CFO, will provide a live presentation relating to the Company's FY22 results via the Investor Meet Company platform on Tuesday, 18 April 2023 at 12.30pm.

The presentation is open to all existing and potential shareholders and registration can be completed via the following link: https://www.investormeetcompany.com/diaceutics-plc/register-investor

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Nick Harland
Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREASDXFELDEFA